Dianthus Therapeutics (DNTH)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	33.90 mm	33.90 mm	33.90 mm	33.90 mm	33.90 mm	33.90 mm
Cash burn (monthly)	93.45 mm	10.29 mm	9.97 mm	6.91 mm	7.09 mm	5.22 mm
Cash used (since last report)	444.73 mm	48.96 mm	47.43 mm	32.88 mm	33.74 mm	24.82 mm
Cash remaining	-410.83 mm	-15.06 mm	-13.53 mm	1.02 mm	161.24 k	9.08 mm
Runway (months of cash)	-4.4	-1.5	-1.4	0.1	0.0	1.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

DNTH institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	97	80	+21.3%
Opened positions	25	31	-19.4%
Closed positions	8	30	-73.3%
Increased positions	32	18	+77.8%
Reduced positions	21	14	+50.0%

13F shares	Current	Prev Q	Change
Total value	856.60 bn	767.92 bn	+11.5%
Total shares	38.61 mm	36.31 mm	+6.4%
Total puts	400.00	0.00	NEW
Total calls	400.00	0.00	NEW
Total put/call ratio	1.0	–	–

Largest owners	Shares	Value	Change
FMR	4.40 mm	$120.56 bn	+0.0%
Bain Capital Life Sciences Investors	3.01 mm	$82.51 bn	0.0%
BCLS Fund III Investments	2.99 mm	$73.13 mm	0.0%
Avidity Partners Management	2.92 mm	$79.87 bn	0.0%
Fairmount Funds Management	2.70 mm	$73.94 bn	-2.2%
Ra Capital Management	2.33 mm	$63.88 bn	0.0%
Octagon Capital Advisors	1.75 mm	$47.82 bn	0.0%
VR Adviser	1.74 mm	$47.76 bn	-16.7%
Venrock Healthcare Capital Partners III	1.74 mm	$48.77 mm	+88.0%
BlackRock	1.64 mm	$45.04 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BlackRock	1.64 mm	+1.64 mm	NEW
BLK BlackRock	0.00	-1.60 mm	EXIT
Alliancebernstein	1.02 mm	+998.13 k	+3990.9%
Venrock Healthcare Capital Partners III	1.74 mm	+816.67 k	+88.0%
Great Point Partners	275.00 k	-482.93 k	-63.7%
STT State Street	821.13 k	+413.43 k	+101.4%
VR Adviser	1.74 mm	-350.00 k	-16.7%
JHG Janus Henderson	949.33 k	+273.67 k	+40.5%
Point72 Asset Management	437.70 k	+263.50 k	+151.3%
Adage Capital Partners GP, L.L.C.	0.00	-250.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DNTH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Feb 25	Marino Garcia	Stock Option Common Stock	Grant	Acquire A	No	No	22.07	340,000	7.50 mm	340,000
3 Feb 25	Simrat Randhawa	Stock Option Common Stock	Grant	Acquire A	No	No	22.07	150,000	3.31 mm	150,000
3 Feb 25	Veness Adam M	Stock Option Common Stock	Grant	Acquire A	No	No	22.07	100,000	2.21 mm	100,000
3 Feb 25	Carr Edward	Stock Option Common Stock	Grant	Acquire A	No	No	22.07	60,000	1.32 mm	60,000
3 Feb 25	Ryan Savitz	Stock Option Common Stock	Grant	Acquire A	No	No	22.07	150,000	3.31 mm	150,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics

20 Dec 24

TD Cowen Initiates Coverage On Dianthus Therapeutics with Buy Rating

20 Dec 24

TD Cowen analyst Yaron Werber initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating.

Press releases

From Benzinga Pro

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

30 Jan 25

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement